361
Participants
Start Date
May 29, 2014
Primary Completion Date
November 6, 2015
Study Completion Date
September 10, 2021
Nivolumab
Cetuximab
Methotrexate
Docetaxel
Local Institution - 0064, Taipei
Local Institution - 0065, Tainan City
Local Institution - 0015, Berazategui
Local Institution - 0013, San Miguel de Tucumán
Local Institution - 0014, Córdoba
Local Institution - 0051, Zurich
Local Institution, Torino
Local Institution - 0047, Berlin
Local Institution - 0007, Pittsburgh
Local Institution, Milan
Local Institution, Milan
Local Institution - 0052, Hamburg
Dumc, Durham
Local Institution - 0034, Madrid
Local Institution - 0001, Atlanta
Local Institution - 0046, Hanover
H. Lee Moffitt Cancer Center, Tampa
Local Institution, Padua
Vanderbilt Cancer Clinic, Nashville
Local Institution - 0012, Columbus
Local Institution - 0048, Essen
Local Institution - 0033, Valencia
Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola
University Of Michigan, Ann Arbor
Local Institution - 0049, Bonn
Local Institution - 0031, Milwaukee
Local Institution - 0002, Chicago
Local Institution, Lyon
Local Institution - 0004, Metairie
Univ Of Tx. Md Anderson, Hoston
Local Institution, Napoli
Huntsman Cancer Institute, Salt Lake City
Stanford University Medical Center, Stanford
Local Institution, Villejuif
Local Institution - 0050, Würzburg
Local Institution - 0060, Kashiwa
Local Institution - 0059, Sunto-gun
Local Institution - 0056, Nagoya
Local Institution - 0063, Takatsuki
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Local Institution - 0054, Ijuí
Local Institution, Porto Alegre
Local Institution - 0055, São Paulo
Local Institution - 0038, Vancouver
Local Institution - 0045, London
Local Institution, Nice
Local Institution, Hong Kong
Local Institution - 0062, Sapporo
Local Institution - 0058, Kobe
Local Institution - 0057, Akashi, Hyogo
Local Institution - 0061, Tokyo
Local Institution, Amsterdam
Local Institution, Groningen
Local Institution, Leiden
Local Institution - 0067, Seoul
Local Institution - 0066, Seoul
Local Institution - 0032, Barcelona
Local Institution - 0035, Barcelona
Local Institution, London
Local Institution, Manchester
Local Institution, Southampton
Local Institution, Metropolitan Borough of Wirral
Local Institution, Surrey
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY